# Azacitidine and Pembrolizumab in Pancreatic Cancer

> **NCT03264404** · PHASE2 · COMPLETED · sponsor: **Susan E. Bates** · enrollment: 36 (actual)

## Conditions studied

- Pancreas Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03264404
- **Lead sponsor:** Susan E. Bates
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-01
- **Primary completion:** 2021-10-01
- **Final completion:** 2024-12-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03264404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03264404, "Azacitidine and Pembrolizumab in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03264404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*